Ginkgo Bioworks Holdings (DNA)

Currency in USD
6.790
-0.450(-6.22%)
Closed·
6.954+0.164(+2.42%)
·

DNA Financial Summary

Key Ratios

P/E Ratio-1.29
Price/Book1.21
Debt / Equity96.15%
Return on Equity-59.94%
Dividend Yield0.00%
EBITDA-267.82M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

0 Buy
1 Hold
2 Sell
Ratings:
3 analysts
Overall Consensus
Sell

Analysts 12-Month Price Target:

Average 7.000
(+3.09% Upside)

Earnings

Latest Release
Aug 05, 2026
EPS / Forecast
-0.92 / -1.05
Revenue / Forecast
20M / 29.9M
EPS Revisions
Last 90 days

FAQ

What were Ginkgo Bioworks's earnings for the latest quarter?

The Ginkgo Bioworks EPS (TTM) is -5.284. Ginkgo Bioworks reported sales of 20.156, net income of -46.710, and EPS of -0.920 for the latest quarter.

What was Ginkgo Bioworks's net income for the latest quarter?

Ginkgo Bioworks's net income for the latest quarter was -46.710.

How did Ginkgo Bioworks's performance compare year-over-year in the latest quarter?

The company's revenue moved from 19.474 million USD in the previous quarter to 20.156 million USD in the latest quarter, and net income moved from -82.587 million USD to -46.710 million USD compared to the previous quarter.

What is Ginkgo Bioworks's net profit margin on a TTM basis?

Ginkgo Bioworks's trailing twelve months (TTM) net profit margin is -219.605%.

How does Ginkgo Bioworks's debt to equity ratio compare to industry standards?

Ginkgo Bioworks's total debt-to-equity ratio is 96.152%.

What is Ginkgo Bioworks's return on investment on a TTM basis?

Ginkgo Bioworks's trailing twelve months (TTM) return on investment (ROI) is -59.936%.

How has Ginkgo Bioworks's total revenue grown this year?

Ginkgo Bioworks's total revenue was 19.474 million USD in the previous quarter and 20.156 million USD in the latest quarter.

What is Ginkgo Bioworks's gross margin on a TTM basis?

Ginkgo Bioworks's trailing twelve months (TTM) gross margin is 68.042%%.

What was Ginkgo Bioworks's revenue per share for the latest quarter?

Ginkgo Bioworks's revenue per share for the latest quarter was 3.421.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.